Sailong Pharmaceutical Group Co., Ltd. (002898.SZ)

CNY 10.94

(0.46%)

Market Cap (In CNY)

1.92 Billion

Revenue (In CNY)

310.62 Million

Net Income (In CNY)

9.53 Million

Avg. Volume

5.4 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.7-14.35
PE
-
EPS
-
Beta Value
0.11
ISIN
CNE1000032S5
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jian Feng Li
Employee Count
-
Website
https://www.sailong.cn
Ipo Date
2017-09-13
Details
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, gaicycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, and pantoprazole sodium products. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding medicine, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.